Research programme: interleukin-16 based therapies - Sedecim Therapeutics
Latest Information Update: 26 Apr 2007
Price :
$50 *
At a glance
- Originator Sedecim Therapeutics
- Class
- Mechanism of Action Interleukin 16 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; HIV infections; Inflammatory bowel diseases; Rheumatoid arthritis
Most Recent Events
- 15 Nov 2001 Preclinical development for Asthma in USA (Unknown route)
- 15 Nov 2001 Preclinical development for HIV infections treatment in USA (Unknown route)
- 15 Nov 2001 Preclinical development for Inflammatory bowel disease in USA (Unknown route)